Current State of U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Traditional Chinese medical practices are more commonly integrated into MDS care in China compared to Western nations. For example, herbal medicines like Huangqi decoction and Shenqi Fuzheng Injection are frequently prescribed as adjunctive treatment. Their mechanisms are not fully understood but may work via immunomodulation or antioxidant effects. Mainstream therapies also parallel the U.S. and Europe, including blood product support, chemotherapy, and allo-HSCT. However, accessibility and affordability of novel drugs remains an issue for many Chinese patients living outside major cities. Hypomethylating agents like azacitidine have only been available nationally since 2016 when included in China's National Reimbursement Drug List (NRDL). Additionally, the practice of allo-HSCT is less developed in China versus Western countries. There are approximately 200 centers performing the procedure annually in China compared to over 500 in the U.S. alone. This is partly due to lacking donor registries and cultural preferences to avoid invasive therapies if possible in early disease stages. Supportive care also emphasizes traditional healing methods over hospice or palliative approaches seen elsewhere. Get More Insights on U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment-https://businessinmyarea.com/news/classification-of-u-s---europe--and-china-myelodysplastic-syndrome--mds--treatment